Star Combo Pharma Ltd. · ASX:S66
Star Combo Pharma — Shareholder Meeting (November 2021)
9 slides from Star Combo Pharma's shareholder meeting presentation, Nov 23, 2021
Slide 1: Annual General Meeting CEO Presentation
STAR COMBO PHARMA LIMITED Annual General Meeting 23 November 2021 CEO Presentation
Slide 2: Key Themes FY21
Key Themes FY21 Resilience in contract manufacturing division despite COVID headwinds Positive operating cash flow of $332K, up from an operating outflow of $1.02M (FY20) Negative COVID impact on earnings with $6.3M non-cash asset write-down of Austoyou and Koala Mall Construction and upgrade
Slide 3: Our people
Our people People Safety COVID Our team have demonstrated As a manufacturing business, A comprehensive COVID agility and tenacity in guiding we are dedicated to ensuring safety plan has been the business through the we have a safe workplace. implemented at Star Combo. uncertain COVID environment and
Slide 4: Business Division Update
Business Division Update Manufacturing Division (OEM and Branded) – OEM division performed ahead of expectations with increasing volume of bulk orders manufactured due to new customers – 76 new customer accounts acquired with the strongest order book in place for 2022 – Through new product develop
Slide 5: Q1 FY22 Trading Update
Q1 FY22 Trading Update Q1 FY22 Revenue of $5.8M (Q4 FY21 $6.0M) – OEM division performed ahead of expectations – Supply chain limitations, expected to ease as travel restrictions lift – Retail division continues to be impacted by COVID related restrictions Q1 FY22 Customer cash receipts of $5.3M
Slide 6: Increase in production volume Q1 FY22
Increase in production volume Q1 FY22 Manufacturing division continues to perform strongly A good start in Q1 FY22, production volume increased by 24% when compared with Q1 FY21 Units Manufactured Qty: million Q1 FY21 production volume increased by 24% to Q1 FY22 250 200 150 100 50 - Q1 FY21 Rem
Slide 7: Achievements & Outlook
Achievements & Outlook Construction of Contract manufacturing FY21 Continued growth in Operating cash flow contract manufacturing positive with $17.3M in multimillion-dollar, business remains Achievements division cash in bank manufacturing facilities to increase capacity resilient in face of COVID
Slide 8: Thank You
Investor relations investors@starcombo.com.au THANK YOU 8
Slide 9: Disclaimer
DISCLAIMER The information in this presentation is not a prospectus or other form of disclosure document prepared in accordance with the requirements of the Corporations Act 2001 (Cth) (Corporations Act) and will not be lodged with the Australian Securities and Investments Commission (ASIC). This pr
Star Combo Pharma — Shareholder Meeting (November 2021) on 6ix